Eikon Therapeutics clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.

1. Minor

   EIK1001 in Combo With Pembro Versus Placebo and Pembro as…EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy · Advanced Melanoma

   Trial sites expanded: 107 → 127 locations

   Eikon Therapeutics·Phase 2/3· NCT06697301· Registry history of NCT06697301 on ClinicalTrials.gov (opens the registry)

   Oct 6, 2026

2. Minor

   TeLuRide-008 · EIK1001 in Combination With Pembrolizumab and…TeLuRide-008 · EIK1001 in Combination With Pembrolizumab and Chemotherapy · Stage 4 Non-Small Cell Lung Cancer

   Trial sites expanded: 24 → 28 locations

   Eikon Therapeutics·Phase 2/3· NCT07365319· Registry history of NCT07365319 on ClinicalTrials.gov (opens the registry)

   Oct 2, 2026

3. Minor

   EIK1005-002 · Research Study Evaluating EIK1005, a Werner…EIK1005-002 · Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab · Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

   Trial sites expanded: 10 → 35 locations

   Eikon Therapeutics·Phase 1/2· NCT07262619· Registry history of NCT07262619 on ClinicalTrials.gov (opens the registry)

   Sep 22, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.